Related Experiment Video

Updated: Jul 22, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Pneumococcal conjugate vaccine for young children

R K Zimmerman1

  • 1Department of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.

American Family Physician
|June 5, 2001
PubMed

Insights

The pneumococcal conjugate vaccine (PCV) significantly reduces invasive pneumococcal disease. This vaccine shows high efficacy in infants and children, preventing serious infections like meningitis and pneumonia.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Streptococcus pneumoniae causes significant morbidity and mortality from meningitis, pneumonia, and otitis media annually in the US.
  • Pneumococcal conjugate vaccine (PCV) was introduced in 2000 to target prevalent serotypes responsible for invasive infections in young children.

Purpose of the Study:

  • To evaluate the efficacy of the pneumococcal conjugate vaccine against invasive pneumococcal disease.
  • To outline the recommended vaccination schedule and target populations for PCV.

Main Methods:

  • A large randomized, double-blind, controlled trial was conducted to assess vaccine efficacy.
  • Follow-up analysis was performed eight months post-trial to determine sustained efficacy.

Main Results:

  • The PCV demonstrated 100% efficacy against invasive pneumococcal disease in the primary analysis.
  • Follow-up analysis confirmed 94% efficacy against invasive disease for the targeted serotypes.
  • The standard infant vaccination schedule includes doses at 2, 4, 6, and 12-15 months of age.

Conclusions:

  • The pneumococcal conjugate vaccine is highly effective in preventing invasive pneumococcal disease in children.
  • Routine infant vaccination and catch-up vaccination for at-risk children are recommended by the American Academy of Family Physicians.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...